EU-US trade deal could add up to $19 billion in pharma industry costs, analysts say
(Reuters) -The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 billion as branded medicines become subject to a tariff of 15%, analysts said on Monday.
The added costs could raise prices for consumers unless pharmaceutical companies take action to mitigate the impact of the tariffs, one of the analysts said.
Pharmaceuticals had historically been exempt from duties. Medicines are the largest European exports to the United States by value and the EU accounts for about 60% of all pharmaceutical imports to the U.S.
On Sunday, European officials said that a bilateral trade deal for an across-the-board 15% tariff included pharmaceuticals, except for some generic drugs, which would be subject to no tariffs.
The U.S. has been conducting a national security investigation into the pharmaceutical sector and the industry has been bracing for separate sectoral tariffs. President Donald Trump said earlier this month, before negotiating the bilateral deal, that pharmaceutical tariffs could be as high as 200%.
Some Wall Street analysts said that they do not expect additional tariffs on the EU as a result of the investigation, but others cautioned that the deal was not yet signed and that several questions remained unanswered.
UBS analyst Matthew Weston said that he expects details of the trade deal to include protective measures for EU pharma exports from the U.S. investigation, especially since such measures are being discussed in negotiations with the United Kingdom and Switzerland.
ING analyst Diederik Stadig also said that while tariffs on top of the 15% were not expected, even after the conclusion of the national security investigations, nothing is completely clear "until a trade deal is inked."
Stadig estimates that these levies could add $13 billion to industry expenses without any mitigation strategies, and some of that could be ultimately borne by the consumer.
Bernstein analyst Courtney Breen puts the additional expenses at $19 billion for the industry, but she notes that companies might be able to absorb some of the costs with the measures they have been implementing — such as stockpiling of drug products and new deals with contract researchers.
Earlier this month, Sanofi said it will sell a manufacturing facility in New Jersey to Thermo Fisher, where the French drugmaker's therapies will continue to be manufactured. Roche's CEO Thomas Schinecker said last week that the company was increasing its U.S. inventories to avoid any immediate disruption from tariffs.
UBS' Weston said that it was not immediately clear which generic drugs were exempted from duties under the deal, but any impact for generic drugmaker Sandoz for this year should mostly be manageable.
Shares in pharmaceutical companies Sanofi, Roche and Sandoz Group all closed up between 0.5% and 1% on Monday.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
7 minutes ago
- New York Times
How the E.U. Wooed Trump With Flashy but Flimsy Numbers
When Donald Trump unveiled his trade deal with the European Union on Sunday night, he fixated on its size. And when the White House later released a fact sheet on the agreement, it trumpeted pledges by the Europeans for big investments in the United States. 'The E.U. will purchase $750 billion in U.S. energy and make new investments of $600 billion in the United States, all by 2028,' the document declared. But when the European Union released its own fact sheet on Tuesday, its description of that pledge was more muted — and far more noncommittal on spending outside of energy. 'E.U. companies have expressed interest in investing at least $600 billion' in 'various sectors in the U.S.,' the document explained. There's a reason for the equivocation: The European commitments are more like vague estimates than specific promises. The spending would come from private companies across the 27-nation bloc and would not be directed or enforced by European Union officials. The European Commission, the European Union's executive branch that is responsible for negotiating trade, can play a role in convening, organizing and encouraging big spending, but it cannot compel such outlays. Want all of The Times? Subscribe.
Axios
8 minutes ago
- Axios
Trump's plan to boost U.S. automakers is squeezing them instead
A consequence of President Trump's new trade deals with Japan and the European Union is that they could entice foreign automakers to import even more cars to the U.S., rather than grow their American operations. Why it matters: Trump's effort to reshape global commerce assumes that punishing tariffs on imports will force foreign manufacturers to set up factories in America, strengthening the U.S. economy. But his trade policy conflicts in many ways with those industrial policy goals, for now at least, by making it cheaper to import cars than to build them in North America. The big picture: That's probably not the case forever. Trump's penchant for one-off trade deals with individual countries means some will have agreements before others. But neither U.S. automakers nor the United Auto Workers are happy about the advantages their competitors have at the moment. Where it stands: Tariffs on cars imported from Japan or Europe will face a 15% tariff, starting Aug. 1, in lieu of a 25% tax hike the U.S. imposed on all imported vehicles and car parts earlier this year. It might seem like a reprieve, but it's still sharply higher than the 2.5% they had been paying before Trump took office. U.S.-built cars, by contrast, are taxed 25% on imported parts (except for those that comply with the U.S.-Mexico-Canada trade agreement signed by Trump in his first term). That applies not just to the Detroit 3 carmakers, but also to foreign automakers with U.S. plants. Plus, they're subject to 50% tariffs on imported steel, aluminum and soon, copper. Cars built in Canada and Mexico, already taxed at 25%, face even higher tariffs beginning Aug. 1. For Canada, the new rate would be 35%; for Mexico, 30%. Many companies build vehicles in Canada or Mexico and ship them to the U.S. Winners and losers: For now, the winners of Trump's head-spinning trade policies are Japan, the UK and the EU, James Schmidt, vice president-autos for the Oliver Wyman consultancy, tells Axios. At least those countries can move forward with their strategies for serving the U.S. market, he said. Losers are the countries still negotiating, like South Korea, Mexico and Canada, as well as U.S. automakers that produce vehicles in those countries. Trump has said tariffs will go up on Aug. 1 if no deal is reached. "It's a big jigsaw puzzle right now," says Schmidt. "The rest of the pieces still have to fall into place." In the short term, he said, Japanese and European carmakers may be enticed to import more cars to the U.S., even with the 15% tariff, to avoid other levies. What they're saying:"U.S. trade policy should push automakers to build in America, with skilled, union labor. A flat 15% tariff doesn't accomplish that," the UAW, which previously backed Trump's tough talk on tariffs, said in a statement. "In fact, when left unchecked, companies often respond by shifting final assembly and supply chains to even lower-cost countries—making the situation for workers far worse. American workers deserve more than empty promises. They deserve a trade policy that delivers real jobs and a real future." The other side:"No president has taken a greater interest in restoring American auto industry dominance than President Trump, and the Administration is in constant touch with the auto industry to meet this objective," White House spokesperson Kush Desai told Axios. He pointed to trade deals that open up market access in Japan and Europe for American brands, as well as efforts to expand domestic metals production. The bottom line: It's difficult to predict the future, but U.S. trade policy is starting to become clearer, David Steinert, a partner in the automotive and industrial practice at the consulting firm AlixPartners, tells Axios via email.
CBS News
8 minutes ago
- CBS News
Trump gives Russia 10 days to reach ceasefire agreement with Ukraine — or else face secondary sanctions
President Trump on Tuesday set a 10-day deadline for Russia to reach a ceasefire agreement with Ukraine, or else it risks secondary sanctions, which would mean the Kremlin would have to make a deal with Ukraine by Friday, Aug. 8. The president, who said in Scotland on Monday that he was shortening his original 50-day deadline for Russia to make peace with Ukraine, spoke to reporters about the revised deadline Tuesday aboard Air Force One as he returned to the U.S. Mr. Trump has been in Scotland for the last five days to negotiate trade deals with European leaders and visit his two golf resorts there. "Ten days from today. Okay?" he said on the plane. "And then you know, we're going to put on tariffs and stuff, and I don't know if it's going to affect Russia, because he wants to obviously probably keep the war going," the president added, seemingly speaking about Russian President Vladimir Putin. "But we're going to put on tariffs and the various things that you put on. It may or may not affect them, but it could." The U.S. and Ukraine have been pushing for an immediate ceasefire in order to negotiate a lasting peace deal. Earlier in July, Mr. Trump said if Russia doesn't agree to a ceasefire within a 50-day window, the U.S. would impose secondary tariffs of up to 100% on goods sold by countries that do business with Russia. Mr. Trump has increasingly expressed frustration with Putin, questioning whether the Russian leader really wants to end the war with Ukraine. Mr. Trump has described thinking he'd had a good phone call with the Russian leader, only to find that the next day, more Ukrainians were being killed by Russia. "I always hang up, [and] say, 'Well, that was a nice phone call,'" Mr. Trump said earlier in July. "And then missiles are launched into Kyiv or some other city, and I say, 'That's strange.' And after that happens three or four times, you say, the talk doesn't mean anything." It's a change from earlier this year, when Mr. Trump said he thought Putin "wants peace." On Monday, Mr. Trump said he was "very disappointed" in Putin over Moscow's continued bombing of Ukraine, narrowing Russia's timeframe for a deal from 50 days to 10 or 12. "There's no reason in waiting," Mr. Trump said Monday. "We just don't see any progress being made."Tucker Reals and Weijia Jiang contributed to this report.
